Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Recro Pharma logo — Pioneering non-opioid pain therapeutics for post-surgical ca...

Recro Pharma

Pioneering non-opioid pain therapeutics for post-surgical care.

Founded 2007 Post-IPO Equity Total: $274.80M Biotechnology, Health Care +1

General Information

Company Name Recro Pharma
Founded Year 2007
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Recro Pharma. To contact Recro Pharma, visit recropharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Recro Pharma compare?

A PDF of Recro Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Recro Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Recro Pharma

Recro Pharma is a clinical-stage specialty pharmaceutical company based in Malvern, Pennsylvania, pioneering non-opioid pain therapeutics for post-surgical care. Founded in 2007, the company specializes in non-opioid pain treatments, particularly for postoperative care. Recro Pharma's leading product is an intranasal formulation of Dexmedetomidine (Dex), which has shown promising results in an effective pain relief capacity, as indicated by the successful completion of a Phase Ib placebo-controlled trial. The company's last investment stood at $8.30M in Post-IPO Equity, which was made on 24 August 2023. The investors involved in this funding round were not disclosed. Overall, Recro Pharma's focus on developing non-opioid pain treatments in the postoperative care space positions it well in addressing the growing concerns around opioid usage. With a solid product in its pipeline and recent investment, the company appears to be making strides in its mission to provide alternative pain management solutions.

Business keywords: Recro Pharma, pharmaceutical company, non-opioid pain therapeutics, postoperative care, Dexmedetomidine, clinical-stage, specialty pharmaceuticals, Malvern, Pennsylvania, intranasal formulation, Phase Ib trial, pain relief, drug development, innovative therapeutics

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $8.30M -
24 Aug 2023
Post IPO Equity $30.00M -
12 May 2021
Post IPO Debt $40.50M 1
Athyrium Capital Management
Athyrium Capital Management
04 Mar 2019
Post IPO Equity $40.00M 1
Cowen Investment Management
29 Dec 2017
Post IPO Debt $100.00M 1
Athyrium Capital Management
Athyrium Capital Management
20 Nov 2017
Post IPO Equity $40.00M -
16 Dec 2016
Post IPO Equity $16.00M 1
Broadfin Capital
Broadfin Capital
13 Jul 2015

Recro Pharma Alternatives & Competitors

View All Alternatives
Recro Pharma vs
Baudax Bio
Baudax Bio United States

Advancing Acute Care Therapeutics

Post-IPO Equity
12 employees
Biotechnology, Health and Wellness
Recro Pharma vs
Vitalis Pharma
Vitalis Pharma United States

Aiming to Improve Patients'​ Lives in Multiple Sclerosis, Post-op Pain (Non-opioid), and Dyslipidemi...

2 employees
Health Care, Manufacturing
Recro Pharma vs
Scilex Holding Company
Scilex Holding Company United States

Striving to Revolutionize the World of Non-Opioid Pain Management

Post-IPO Debt
104 employees
Health Care, Pharmaceutical
View all alternatives

FAQ About Recro Pharma

Pioneering non-opioid pain therapeutics for post-surgical care.
Recro Pharma was founded in 2007.
Recro Pharma operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Recro Pharma, pharmaceutical company, non-opioid pain therapeutics and postoperative care.
Recro Pharma has completed 7 funding rounds, raising a total of $274.80M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Recro Pharma include Baudax Bio, Vitalis Pharma, Scilex Holding Company, MacuCLEAR, Trimel Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Recro Pharma and Baudax Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Recro Pharma, https://bouncewatch.com/company/recro-pharma, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes